138 related articles for article (PubMed ID: 37799222)
1. A Single-Center Retrospective Review of Patients with Suspected Malignant Hyperthermia Susceptibility.
Edwards C; Dooley FC; Gonzalez S; Austin TM; Gravenstein N
Cureus; 2023 Sep; 15(9):e44661. PubMed ID: 37799222
[TBL] [Abstract][Full Text] [Related]
2. Masseter muscle rigidity and malignant hyperthermia susceptibility in pediatric patients. An update on management and diagnosis.
O'Flynn RP; Shutack JG; Rosenberg H; Fletcher JE
Anesthesiology; 1994 Jun; 80(6):1228-33. PubMed ID: 8010468
[TBL] [Abstract][Full Text] [Related]
3. Autosomal dominant canine malignant hyperthermia is caused by a mutation in the gene encoding the skeletal muscle calcium release channel (RYR1).
Roberts MC; Mickelson JR; Patterson EE; Nelson TE; Armstrong PJ; Brunson DB; Hogan K
Anesthesiology; 2001 Sep; 95(3):716-25. PubMed ID: 11575546
[TBL] [Abstract][Full Text] [Related]
4. Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and the ryanodine-contracture-test results in MH susceptible, normal and control muscle.
Hartung E; Koob M; Anetseder M; Schoemig P; Krauspe R; Hogrefe G; Engelhardt W
Acta Anaesthesiol Scand; 1996 Apr; 40(4):437-44. PubMed ID: 8738688
[TBL] [Abstract][Full Text] [Related]
5. Use of the caffeine-halothane contracture test for the diagnosis of malignant hyperthermia in Brazil.
Sudo RT; Cunha LB; Carmo PL; Matos AR; Trachez MM; Cardoso LA; Aguiar MI; Abreu AV; Zapata-Sudo G
Braz J Med Biol Res; 2010 Jun; 43(6):549-56. PubMed ID: 20464345
[TBL] [Abstract][Full Text] [Related]
6. [Registration of peranesthetic cases of malignant hyperthermia in France. An update].
Jacquot C; Stieglitz P; Kozak-Reiss G; Krivosic-Horber R; Laxenaire MC; Lienhart A; Nivoche Y
Ann Fr Anesth Reanim; 1988; 7(6):524-34. PubMed ID: 3223647
[TBL] [Abstract][Full Text] [Related]
7. Management of patients susceptible to malignant hyperthermia: A surgeon's perspective.
Carlson KJ; Sun SA; Swan C; Koenig M; Derkay CS
Int J Pediatr Otorhinolaryngol; 2022 Aug; 159():111187. PubMed ID: 35660936
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the segregation of the RYR1 C1840T mutation with segregation of the caffeine/halothane contracture test results for malignant hyperthermia susceptibility in a large Manitoba Mennonite family.
Serfas KD; Bose D; Patel L; Wrogemann K; Phillips MS; MacLennan DH; Greenberg CR
Anesthesiology; 1996 Feb; 84(2):322-9. PubMed ID: 8602662
[TBL] [Abstract][Full Text] [Related]
9. Malignant Hyperthermia Susceptibility and Fitness for Duty.
Lee MA; McGlinch EB; McGlinch MC; Capacchione JF
Mil Med; 2017 Mar; 182(3):e1854-e1857. PubMed ID: 28290972
[TBL] [Abstract][Full Text] [Related]
10. Is there a link between exertional heat stroke and susceptibility to malignant hyperthermia?
Sagui E; Montigon C; Abriat A; Jouvion A; Duron-Martinaud S; Canini F; Zagnoli F; Bendahan D; Figarella-Branger D; Brégigeon M; Brosset C
PLoS One; 2015; 10(8):e0135496. PubMed ID: 26258863
[TBL] [Abstract][Full Text] [Related]
11. Safety of general anesthesia in patients previously tested negative for malignant hyperthermia susceptibility.
Allen GC; Rosenberg H; Fletcher JE
Anesthesiology; 1990 Apr; 72(4):619-22. PubMed ID: 2321777
[TBL] [Abstract][Full Text] [Related]
12. The differential effect of halothane and 1,2-dichlorohexafluorocyclobutane on in vitro muscle contractures of patients susceptible to malignant hyperthermia.
Kindler CH; Girard T; Gong D; Urwyler A
Anesth Analg; 2002 Apr; 94(4):1028-33, table of contents. PubMed ID: 11916818
[TBL] [Abstract][Full Text] [Related]
13. [Diagnosis of malignant hyperthermia susceptibility. 1. The significance of in vitro susceptibility tests].
Mortier W; Breucking E
Anaesthesist; 1993 Oct; 42(10):675-83. PubMed ID: 8250201
[TBL] [Abstract][Full Text] [Related]
14. Mutation screening in the ryanodine receptor 1 gene (RYR1) in patients susceptible to malignant hyperthermia who show definite IVCT results: identification of three novel mutations.
Rueffert H; Olthoff D; Deutrich C; Meinecke CD; Froster UG
Acta Anaesthesiol Scand; 2002 Jul; 46(6):692-8. PubMed ID: 12059893
[TBL] [Abstract][Full Text] [Related]
15. Malignant hyperthermia.
Halliday NJ
J Craniofac Surg; 2003 Sep; 14(5):800-2. PubMed ID: 14501352
[TBL] [Abstract][Full Text] [Related]
16. In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group.
Ording H; Brancadoro V; Cozzolino S; Ellis FR; Glauber V; Gonano EF; Halsall PJ; Hartung E; Heffron JJ; Heytens L; Kozak-Ribbens G; Kress H; Krivosic-Horber R; Lehmann-Horn F; Mortier W; Nivoche Y; Ranklev-Twetman E; Sigurdsson S; Snoeck M; Stieglitz P; Tegazzin V; Urwyler A; Wappler F
Acta Anaesthesiol Scand; 1997 Sep; 41(8):955-66. PubMed ID: 9311391
[TBL] [Abstract][Full Text] [Related]
17. Malignant hyperthermia in Canada: characteristics of index anesthetics in 129 malignant hyperthermia susceptible probands.
Riazi S; Larach MG; Hu C; Wijeysundera D; Massey C; Kraeva N
Anesth Analg; 2014 Feb; 118(2):381-387. PubMed ID: 23842196
[TBL] [Abstract][Full Text] [Related]
18. Analysis of histomorphology in malignant hyperthermia-susceptible patients.
Orlov D; Keith J; Rosen D; Croul S; Kraeva N; Riazi S
Can J Anaesth; 2013 Oct; 60(10):982-9. PubMed ID: 23888335
[TBL] [Abstract][Full Text] [Related]
19. Referral Indications for Malignant Hyperthermia Susceptibility Diagnostics in Patients without Adverse Anesthetic Events in the Era of Next-generation Sequencing.
van den Bersselaar LR; Hellblom A; Gashi M; Kamsteeg EJ; Voermans NC; Jungbluth H; de Puydt J; Heytens L; Riazi S; Snoeck MMJ
Anesthesiology; 2022 Jun; 136(6):940-953. PubMed ID: 35285867
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
